Public Employees Retirement System of Ohio Has $536,000 Holdings in Fulgent Genetics, Inc. $FLGT

Public Employees Retirement System of Ohio boosted its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 3,217.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,739 shares of the company’s stock after acquiring an additional 32,722 shares during the period. Public Employees Retirement System of Ohio’s holdings in Fulgent Genetics were worth $536,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in FLGT. Farther Finance Advisors LLC increased its holdings in shares of Fulgent Genetics by 69.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after acquiring an additional 548 shares in the last quarter. Kestra Advisory Services LLC bought a new position in shares of Fulgent Genetics during the 4th quarter valued at about $35,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Fulgent Genetics by 214.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after purchasing an additional 1,251 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Fulgent Genetics in the 2nd quarter valued at approximately $49,000. Finally, Flagship Harbor Advisors LLC acquired a new position in shares of Fulgent Genetics in the 4th quarter valued at approximately $56,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on FLGT shares. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Piper Sandler increased their price objective on shares of Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Fulgent Genetics in a report on Monday, July 6th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $27.50.

Fulgent Genetics Price Performance

Shares of Fulgent Genetics stock opened at $18.55 on Wednesday. The firm has a market cap of $510.31 million, a price-to-earnings ratio of -6.58 and a beta of 0.90. The stock’s 50-day moving average is $19.33 and its 200-day moving average is $19.04. Fulgent Genetics, Inc. has a one year low of $13.46 and a one year high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.The firm had revenue of $85.39 million for the quarter, compared to the consensus estimate of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. On average, equities analysts expect that Fulgent Genetics, Inc. will post -2.81 EPS for the current year.

Insider Buying and Selling

In other news, insider Hanlin Gao sold 1,688 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $30,198.32. Following the sale, the insider owned 990,374 shares of the company’s stock, valued at $17,717,790.86. The trade was a 0.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $38,391.94. Following the transaction, the chief operating officer owned 367,605 shares of the company’s stock, valued at $6,576,453.45. The trade was a 0.58% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 5,980 shares of company stock valued at $106,360. Insiders own 36.18% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.